View the new WinRho® eDetail

View the eDetail to learn more about a front-line3 therapy for ITP.

Administration of WinRho® SDF

Administration of WinRho® SDF is convenient, requiring an intravenous infusion over three to five minutes.


Duration of Response

Response duration varies according to treatment groups, but has been shown to reach almost 90 days in adults with chronic ITP.1,2

* Study was performed using WinRho®/WinRho® SD
† Dose = 20-75 µg/kg (100-375 IU/kg); Response = platelet increase to ≥20,000/mm3

WinRho® SDF Liquid is Bioequivalent to WinRho® SDF Lyophilized

In two comparative pharmacokinetic studies (n=101), the formulations were bioequivalent following IV administration based on area under the curve to 84 days and had comparable pharmacokinetics following IM administration. Both formulations also had similar elimination half-lives. WinRho® SDF must be administered via the intravenous route for the treatment of ITP.

Please see Important Safety Information and Prescribing Information.

  1. WinRho® SDF [Rho(D) Immune Globulin Intravenous (Human)] package insert, Cangene Corporation,Winnipeg, Canada. Baxter Healthcare Corporation,WestlakeVillage, CA, USA, April 2006.
  2. Data on file, Cangene Corporation, Baxter Healthcare Corporation.
  3. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood. 2005; 106: 2244-2251.